West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), University of Ghana, Accra, Ghana.
Department of Biochemistry, Cell and Molecular Biology, College of Basic and Applied Sciences, University of Ghana, Accra, Ghana.
Front Immunol. 2021 Feb 3;12:602848. doi: 10.3389/fimmu.2021.602848. eCollection 2021.
Sepsis is a life-threatening systemic illness attributed to a dysregulated host response to infection. Sepsis is a global burden killing ~11 million persons annually. In December 2019, a novel pneumonia condition termed coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged and has resulted in more than 1,535,982 deaths globally as of 8 December 2020. These two conditions share many pathophysiological and clinical features. Notably, both sepsis and COVID-19 patients experience consumptive thrombocytopenia, haemolytic anaemia, vascular microthrombosis, multi-organ dysfunction syndrome, coagulopathy, septic shock, respiratory failure, fever, leukopenia, hypotension, leukocytosis, high cytokine production and high predisposition to opportunistic infections. Considering the parallels in the immunopathogenesis and pathophysiological manifestations of sepsis and COVID-19, it is highly likely that sepsis care, which has a well-established history in most health systems, could inform on COVID-19 management. In view of this, the present perspective compares the immunopathogenesis and pathophysiology of COVID-19 and non-SARS-CoV-2 induced sepsis, and lessons from sepsis that can be applicable to COVID-19 management.
脓毒症是一种危及生命的全身性疾病,其特征是宿主对感染的反应失调。脓毒症是一个全球性的负担,每年导致约 1100 万人死亡。2019 年 12 月,一种新型肺炎疾病被命名为 2019 年冠状病毒病(COVID-19),由严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)引起,截至 2020 年 12 月 8 日,已在全球范围内导致超过 153.5982 人死亡。这两种疾病有许多病理生理学和临床特征。值得注意的是,脓毒症和 COVID-19 患者都经历消耗性血小板减少症、溶血性贫血、血管微血栓形成、多器官功能障碍综合征、凝血障碍、脓毒性休克、呼吸衰竭、发热、白细胞减少症、低血压、白细胞增多症、细胞因子大量产生和易发生机会性感染。鉴于脓毒症和 COVID-19 的免疫发病机制和病理生理表现存在相似之处,在大多数卫生系统中具有悠久历史的脓毒症治疗方法很可能为 COVID-19 的管理提供信息。有鉴于此,本观点比较了 COVID-19 和非 SARS-CoV-2 引起的脓毒症的免疫发病机制和病理生理学,并讨论了脓毒症中可应用于 COVID-19 管理的经验教训。